Proline-rich protein 34 long non-coding RNA (PRR34)

**Proline-rich protein 34 long non-coding RNA (PRR34)** is classified as a long non-coding RNA, which are RNA transcripts longer than 200 nucleotides that do not code for proteins[1]. PRR34 is alternatively known as C22orf26 and FLJ10945. Like many lncRNAs, its functional annotation is limited and there is no evidence indicating it encodes a receptor, enzyme, transporter, or classical therapeutic target. The general role of lncRNAs includes modulation of gene expression at the transcriptional, epigenetic, or post-transcriptional level, mainly through interaction with DNA, RNA, or protein complexes[1][2][3]. However, for PRR34 specifically, there is no clear evidence of its involvement in disease, drug interaction, or utility as a biomarker. PRR34 is not recognized as a therapeutic target in pharmacological or clinical settings. **Additional context:** - The gene/protein name "Proline-rich protein 34" and "C22orf26" both refer to a locus previously annotated as a protein-coding gene, but current consensus and genomic database annotations classify PRR34 as a long non-coding RNA, not a functional protein nor a classical therapeutic target. - lncRNAs as a class can play important regulatory roles in gene expression and disease, but PRR34 itself is not specifically highlighted in the literature as functionally characterized or clinically actionable[2][3][1]. - If a receptor, enzyme, or drug target was expected, this is a misclassification: PRR34 is a lncRNA, not a canonical druggable target. **Summary judgment:** PRR34 is a long non-coding RNA, not an established receptor, protein, or therapeutic target. No specific binding drugs, disease roles, mechanisms of action, or biomarker uses are documented for this molecule. This makes the entry “incorrect” as a classical target.

Other names

Proline-rich protein 34PRR34C22orf26FLJ10945